Patent · US Active

Anti-CD19 antibodies and multi-specific binding proteins

US12428480B2 · kind B2 · utility

0Cited by

0References

11Claims

0Family size

Assignee

Cullinan Therapeutics, Inc. · US

Inventors

Patrick Baeuerle · Gauting, DE
Jennifer Michaelson · Cambridge, US
Bochong Li · Boston, US
Naveen Mehta · Cambridge, US

Key dates

Filing date	Dec 11, 2020
Grant date	Sep 30, 2025
Priority date	—
Expiry date	Dec 25, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are anti-CD 19 antibodies and multi-specific binding proteins that bind CD 19, CD3, and serum albumin. Also provided are pharmaceutical compositions comprising these antibodies or multi-specific binding proteins, expression vectors and host cells for making these antibodies or multi-specific binding proteins, and methods of use of these antibodies or multi-specific binding proteins in treating cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.